Compare Mesoblast Limited (MESO) vs Occidental Petroleum Corporation (OXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Occidental Petroleum Corporation — how do they compare? Mesoblast Limited trades at $16.08 (market cap $2.17B), while Occidental Petroleum Corporation trades at $55.34 (market cap $54.89B). The key difference: Occidental Petroleum Corporation is far larger — about 25.3× Mesoblast Limited's market cap, and Occidental Petroleum Corporation pays a 1.88% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | OXY | |
|---|---|---|
Market Cap | $2.17B | $54.89B |
Sector | Technology | Energy |
52-Week High | $20.96 | $66.24 |
52-Week Low | $12.88 | $38.92 |
Enterprise Value | $2.17B | $75.98B |
Dividend Yield | — | 1.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Occidental Petroleum (OXY) trades at $55.36, up 0.91% with a bullish technical signal. The company shows strong profitability with 22.42% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights capital spending reductions and Permian Basin growth potential. Analyst consensus is positive with a $65.38 price target representing 18% upside potential from current levels.
OXY presents a compelling investment case with improving debt metrics and consistent earnings outperformance. However, declining revenue trends from $36.6B in 2022 to $21.6B in 2025 and oil price sensitivity remain key risks. The stock's premium valuation (P/E 74.14) requires sustained execution to justify current levels amid volatile energy markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →
